Ignite Creation Date:
2024-05-06 @ 7:37 PM
Last Modification Date:
2024-10-26 @ 3:10 PM
Study NCT ID:
NCT06079827
Status:
RECRUITING
Last Update Posted:
2023-10-12
First Post:
2023-10-06
Brief Title:
Impact of Therapeutic Plasma Exchange on RNA Biomarker Expression Levels in Alzheimers Patients
Sponsor:
MaxWell Clinic PLC
Organization:
MaxWell Clinic PLC
Study Overview
Official Title:
Impact of Therapeutic Plasma Exchange on RNA Biomarker Expression Levels in Alzheimers Patients
Status:
RECRUITING
Status Verified Date:
2023-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study will determine if Therapeutic Plasma Exchange removes RNA biomarkers associated with Alzheimers Disease and how quickly those biomarkers reappear after treatment
Detailed Description:
Participants with a diagnosis of Alzheimers or Mild Cognitive Impairment will undergo therapeutic plasma exchange as part of their treatment for the disease as per the AMBAR Trial protocol Patients will undergo one non-invasive tests to assess their microvascular system and complete one online test to assess the degree of cognitive impairment Patients will have their blood drawn pre-plasma exchange immediately post plasma exchange and repeated assessments and blood draws at seven day intervals post plasma exchange ending on the twenty-eighth day after the plasma exchange
Their blood will be analyzed by FBB Biomed to identify the presence of unique RNA biomarkers associated with Alzheimers disease and determine how quickly they regenerate
Their blood will be analyzed by FBB Biomed to identify the presence of unique RNA biomarkers associated with Alzheimers disease and determine how quickly they regenerate
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None